Clinical Trials Available for Differentiated Thyroid Cancer and Medullary Thyroid Cancer: Where do we go from here?

 

Related Videos (117)

Renowned researcher Marcia S. Brose, MD, PhD, examines the growing family of tyrosine kinase inhibitors (TKIs) being used to treat patients with RAI-refractory progressive differentiated thyroid cancer. Dr. Brose was the principal investigator for the clinical trials that resulted in the first FDA approval for a TKI, sorafenib, a drug that can halt the progression of RAI-refractory disease for months or years. Dr. Brose’s discussion also includes a review of combination sorafenib/everolimus, demonstrated to extend progression-free survival in patients who progressed on sorafenib alone, and of the newer agents vemurafenib and cabozantinib, currently in clinical studies.

 

Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®